Sarcopenia influences toxicity and survival in non-small cell lung cancer, and sarcopenia assessment can be factored into ...

FDG PET-derived imaging biomarkers of airway inflammation and their clinical associations in patients with non-small cell ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...

Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

A recent study reveals that continuing immunotherapy beyond disease progression significantly improves survival rates in patients with advanced non-small cell and small cell lung cancers, particularly ...

Agilent Technologies (NYSE:A) recently achieved EU IVDR approval for two new indications of its PD-L1 IHC 28-8 pharmDx kit, expanding treatment options for early-stage NSCLC and advanced melanoma.

AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

The exact survival rate for BRAF-positive NSCLC is not well documented. According to the American Cancer Center, the 5-year survival rate of NSCLC (all types) is: localized (tumor has not spread ...